Facebook Linkedin RSS Twitter Youtube
Home 2024

Otsuka Pharmaceutical

Vertex to Acquire Alpine Immune Sciences for $4.9B, Broadening Kidney Drug Pipeline
Drug Discovery

Vertex to Acquire Alpine Immune Sciences for $4.9B, Broadening Kidney Drug Pipeline

Verily Rolling Along: Google’s Life-Sci Sister Doubles Down on AI
Artificial Intelligence

Verily Rolling Along: Google’s Life-Sci Sister Doubles Down on AI

Supportive Care: OnQuality Treats Cancer’s Side Effects
Cancer

Supportive Care: OnQuality Treats Cancer’s Side Effects

Verily Joins Novartis, Otsuka, Pfizer, and Sanofi in Clinical Trial Alliance
Industry News

Verily Joins Novartis, Otsuka, Pfizer, and Sanofi in Clinical Trial Alliance

Otsuka/Astex AML Candidate Guadecitabine Fails Phase III Trial
Cancer

Otsuka/Astex AML Candidate Guadecitabine Fails Phase III Trial

Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms
Drug Discovery

Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms

Otsuka, Akebia Expand Vadadustat Development Deal to Europe and Beyond
Drug Discovery

Otsuka, Akebia Expand Vadadustat Development Deal to Europe and Beyond

Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug
Drug Discovery

Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug

Lundbeck-Otsuka Alzheimer’s Candidate Fails Phase III Trial
Industry News

Lundbeck-Otsuka Alzheimer’s Candidate Fails Phase III Trial

GW-Otsuka Cannabinoid Cancer Pain Candidate Fails First of 3 Phase III Trials
Cancer

GW-Otsuka Cannabinoid Cancer Pain Candidate Fails First of 3 Phase III Trials

123Page 1 of 3
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.